Skip to main content


06-12-2021 | Exenatide | News

Cardiovascular safety shown for continuous subcutaneous exenatide infusion

A phase 3 cardiovascular safety trial finds exenatide delivered from an osmotic mini-pump to be noninferior to placebo.

04-08-2021 | Exenatide | News

FDA approves exenatide extended-release for pediatric type 2 diabetes

Click through for more information on this expanded indication

04-03-2020 | Exenatide | News

Short-acting exenatide makes little difference to glycemia in type 1 diabetes

Short-acting exenatide “does not seem to have a future” as a standard adjunct treatment in people with type 1 diabetes, say the MAG1C investigators.

Heart and stethoscope

19-08-2019 | GLP-1 agonists | Highlight | News

Meta-analysis demonstrates cardioprotective effect of GLP-1 receptor agonists

Treatment with glucagon-like peptide receptor agonists reduces the risk for major adverse cardiovascular events among people with type 2 diabetes, indicate findings from a large meta-analysis.

08-12-2017 | Cardiovascular outcomes | News

Meta-analysis may support cardioprotective class effect for GLP-1 receptor agonists

A meta-analysis published in The Lancet Diabetes & Endocrinology is suggestive of a class cardioprotective effect for the glucagon-like peptide-1 receptor agonists.

15-09-2017 | Exenatide | EASD 2017 | News

EXSCEL: Near miss for exenatide cardioprotection

The results of the Exenatide Study of Cardiovascular Event Lowering study show that the glucagon-like peptide-1 receptor agonist has a neutral cardiovascular effect, the investigators have reported at the EASD annual meeting, in Lisbon, Portugal.

13-09-2017 | GLP-1 agonists | EASD 2017 | News

Incretins research update

One of the first original research sessions of EASD 2017 included updates from the TECOS, SUSTAIN 6, and DURATION-7 and -8 trials.

13-09-2017 | Exenatide | EASD 2017 | News

DURATION-8: Exenatide efficacy durable to 1 year

The 52-week findings of the DURATION-8 trial show durable glycemic control with the combination of exenatide and dapagliflozin in patients with type 2 diabetes.